10.3 Specialty Pharmacy & Limited-Distribution Drugs

Specialty pharmacy is the segment of the supply chain that handles high-cost, complex, and biologic drugs — typically injectables, infusions, or oral oncology agents — that require special handling, patient support, and often temperature-controlled logistics. For the PTCB Supply Chain exam, you must know what makes a drug "specialty," what limited-distribution drugs (LDDs) are, and how specialty distribution differs from traditional wholesale distribution.

What Makes a Drug "Specialty"

A specialty drug usually has several of these features:

• High cost — often thousands of dollars per fill or per dose; annual therapy costs can exceed $100,000
• Biologic or complex molecule — monoclonal antibodies, fusion proteins, gene therapies, mRNA vaccines
• Special handling — refrigeration (2–8 °C), freezer storage, or ultra-cold chain (e.g. −70 °C for some mRNA vaccines and biologics)
• Patient support services — prior authorization, financial assistance, adherence counseling, side-effect monitoring, nursing visits
• Restricted distribution — the manufacturer limits where the drug can be dispensed

Therapeutic areas that drive specialty volume include oncology, autoimmune/inflammatory disease, HIV, hepatitis C, multiple sclerosis, rare/orphan diseases, and gene therapy.

Cold Chain and Ultra-Cold Chain

Specialty drugs frequently require controlled-temperature logistics from manufacturer to patient:

• Refrigerated (cold chain) — 2–8 °C; monitored data loggers; validated coolers
• Frozen — typically −20 °C or below
• Ultra-cold chain — e.g. −60 to −70 °C for some mRNA products and certain biologics; requires specialized freezers and dry-ice shipping

A break in the cold chain (a temperature excursion) can destroy a biologic and is a suspect-product event under DSCSA. Specialty pharmacies must monitor temperature continuously, document excursions, and quarantine product that has fallen out of range.

Limited-Distribution Drugs (LDDs)

A limited-distribution drug (LDD) is a drug the manufacturer restricts to a select network of specialty pharmacies or distributors. The manufacturer limits the network for several reasons:

• REMS compliance — a Risk Evaluation and Mitigation Strategy (REMS) may require the dispensing pharmacy to enroll patients, collect lab values, or confirm training before dispensing; a small network is easier to manage
• Handling control — a drug that needs ultra-cold chain or special reconstitution is safer in fewer, trained hands
• Data and outcomes — the manufacturer wants consistent data collection on real-world use
• Reimbursement and patient assistance — a limited network can run prior authorization, financial assistance, and copay programs more reliably

LDDs are why two pharmacies of equal size may not carry the same specialty product: the manufacturer simply will not sell it to a pharmacy outside the limited network.

Specialty Distribution Channels

Specialty product flows through one of three main channels:

1. Specialty distributor — a distributor that focuses on specialty/biologic products; buys from the manufacturer and sells to enrolled specialty pharmacies
2. Direct-to-pharmacy (manufacturer direct) — the manufacturer ships directly to the enrolled specialty pharmacy, bypassing the wholesale tier
3. Limited-distribution network pharmacy — the manufacturer contracts with a small set of specialty pharmacies (often owned by a PBM or a national specialty pharmacy company) and routes all LDD volume through them

The traditional big-three primary wholesalers (Cardinal, McKesson, Cencora) operate specialty distribution arms, but a meaningful share of LDD volume goes direct or through a specialty-only distributor.

White, Brown, and Clear Bagging

Beyond how a specialty drug is distributed, the official PTCB outline also names how the product physically reaches the point of administration — the so-called bagging models. These are alternative sources of the product for administration to a patient (a Domain 2 topic) and they drive which benefit pays and who holds inventory:

• White bagging — an external specialty pharmacy (often payer-directed) ships a patient-specific drug directly to the provider office or infusion suite for administration. The provider never buys the drug and bills only for administration; the drug is reimbursed under the pharmacy benefit, not the medical benefit.
• Brown bagging — the specialty pharmacy dispenses the clinician-administered drug to the patient, who stores and transports it to the clinic for administration. This raises chain-of-custody and cold-chain integrity concerns and is widely discouraged by ASHP and NABP for safety reasons.
• Clear bagging — the health system own internal specialty pharmacy dispenses the drug and delivers it internally to the system infusion clinic for administration, effectively in-house white bagging that lets the system retain the pharmacy-benefit revenue.

Contrast these with buy-and-bill, the traditional model in which the provider purchases the drug from a wholesaler, stocks it, administers it, and bills both the drug (J-code) and administration under the medical benefit. Payers favor white and clear bagging to shift spend to the pharmacy benefit, reduce provider markups, and capture rebates; providers raise concerns about treatment delays when a dose changes same-day, drug waste from patient-specific dispensing, and lost margin. Several states have enacted restrictions on mandatory white bagging.

Diagram — Specialty Distribution Flow

The flow below shows how a specialty biologic moves from manufacturer to patient, with REMS enrollment and cold-chain handling as gating steps:

In Practice

A patient starting a specialty biologic for severe plaque psoriasis might find that the drug is an LDD: only a handful of specialty pharmacies in the country can dispense it. The pharmacy must enroll the patient in the manufacturer's REMS, verify prior authorization with the payer, arrange cold-chain shipping, and provide adherence counseling. The drug moves manufacturer → specialty distributor → specialty pharmacy → patient, with a temperature data logger inside the shipper. If the logger shows an excursion, the pharmacy quarantines the product and reports a suspect-product event under DSCSA.

Worked Example — Why a Chain Pharmacy May Not Carry an LDD

A retail chain with 8,000 stores asks why it cannot stock a new oncology biologic for a local patient. The answer is not size or capability — it is the manufacturer's limited-distribution network. The biologic requires REMS enrollment, ultra-cold chain, and outcomes data, so the manufacturer has contracted with only three specialty pharmacies nationwide. The patient's prescription must be routed to one of those three. The chain's specialty arm may or may not be one of them; if it is not, the drug simply will not arrive at the local store. This is the defining feature of an LDD and a common exam scenario.